Clinical trials: Epithelial Ovarian Cancer
Ovarian Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)
This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian…
- Trial name
- NCT01863693
- Where
- 30 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Primary Peritoneal
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian…
- Conditions
- Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers
- Trial name
- NCT06751485
- Testing
- JSKN003, Doxorubicin, Paclitaxel
- Volunteers
- 430 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
- Trial name
- NCT06730347
- Testing
- Lorigerlimab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- MacroGenics
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759600
- Testing
- Niraparib
- Where
- 33 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Takeda
Recurrent Ovarian Carcinoma
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a…
- Trial name
- NCT03690739
- Testing
- Carboplatin, Gemcitabine, Bevacizumab
- Where
- 29 sites in Germany
- Volunteers
- 9 people
- Sponsor
- AGO Research GmbH
Recurrent Platinum Resistant Ovarian Cancer
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell…
- Trial name
- CONCERTO (NCT02889900)
- Testing
- cediranib and olaparib
- Where
- 25 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
Ovarian cancer may be caused by a build-up of genetic defects, or damaged genes within the cells of the body. Because the genes are damaged, the body is unable to produce a group of proteins called cytokines which are used by the…
- Trial name
- NCT00137865
- Testing
- EGEN-001 (phIL-12-005/PPC)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- EGEN, Inc.
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory…
- Conditions
- Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Trial name
- NCT03874455
- Testing
- Tazemetostat
- Sponsor
- Epizyme, Inc.
Ovarian Cancer
Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer
The purpose of this study is to determine the maximum tolerated dose of Genexol®-PM plus Carboplatin and evaluate the efficacy and safety of Genexol®-PM plus Carboplatin regimen in subjects with advanced ovarian cancer.
- Trial name
- NCT00877253
- Testing
- Genexol-PM 220mg/㎡, Carboplatin 5AUC, Genexol-PM 260mg/㎡, Carboplatin 5AUC, Genexol-PM 300mg/㎡, Carboplatin 5AUC
- Volunteers
- 18 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Advanced Solid Tumors, Pancreatic Carcinoma
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies.
- Conditions
- Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
- Trial name
- NCT06799637
- Testing
- XNW28012
- Where
- 24 sites in China
- Volunteers
- 350 people
- Sponsor
- Evopoint Biosciences Inc.
Ovarian Cancer, Endometrial Cancer
An Exploratory Study of Detection of Endometrial and Ovarian Cancers in Vaginal Samples Retrieved by the Ellele Sampling Device
An exploratory study of early detection and investigation of gynaecological diseases Throughout a woman's life, she may need tests that can feel uncomfortable, such as a smear test or a biopsy taken through the vagina.
- Trial name
- NCT07429799
- Testing
- Ellele Sampling Device
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ellele Health
Epithelial Ovarian Cancer
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease…
- Trial name
- CAN-003X (NCT01617629)
- Testing
- MUC1 Dendritic Cell Vaccine (Cvac)
- Where
- 6 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Prima BioMed Ltd
Ovarian Cancer, Fallopian Tube Cancer
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT00318370
- Testing
- Farletuzumab, Chemo Plus Far
- Where
- 20 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Morphotek
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05877599
- Testing
- NT-175
- Where
- 20 sites in United States
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Niraparib is an oral inhibitor of poly adenosine diphosphate-ribose polymerase (PARP)-1 and PARP-2. This study will evaluate safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in participants with…
- Trial name
- NCT03326193
- Testing
- Niraparib, Bevacizumab
- Where
- 29 sites in United States
- Volunteers
- 105 people
- Sponsor
- Tesaro, Inc.
Hepatocellular Carcinoma (HCC), Ovarian Cancer
NK521 in the Treatment of Advanced Solid Tumors
Eligible subjects with advanced hepatocellular carcinoma and ovarian cancer will be divided into two treatment groups based on the volume of ascites.
- Conditions
- Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
- Trial name
- NCT07657416
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Ovarian Cancer
Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
This a Phase 2, multicenter open label, uncontrolled 2-step design. Patients will be arranged in two groups based upon the response to their last platinum containing therapy.
- Trial name
- NCT00610792
- Testing
- bortezomib, pegylated liposomal doxorubicin
- Where
- 7 sites in Italy, Switzerland
- Volunteers
- 91 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.